立体定向MRI引导自适应放疗(SMART)治疗局部晚期胰腺癌:前瞻性单中心队列研究
该前瞻性单中心队列研究在MOMENTUM方案(NCT04075305)下,评估118例局部晚期胰腺癌(LAPC)患者接受消融性立体定向MRI引导自适应放疗(SMART,50 Gy/5次)的疗效与毒性。自首次SMART起中位总生存(OS)为13.2个月,2年OS率23.9%;中位无进展生存(PFS)5.6个月;1年、2年局部进展累积发生率分别为15.0%和22.2%。结论认为SMART局部控制令人鼓舞且严重毒性有限,远处进展仍是主要失败模式。
要点
- 118例LAPC患者接受SMART 50 Gy/5次,自首次治疗起中位OS为13.2个月。
- 1年局部进展累积发生率15.0%,2年为22.2%,远处进展为主要失败模式。
- 急性≥III级胃肠道毒性5.4%(6/112),晚期≥III级毒性3.2%(3/93)。
核心结论
- SMART在LAPC中提供令人鼓舞的局部控制且严重毒性有限,但远处进展仍是主要失败模式。
研究设计与样本
- 前瞻性单中心队列研究,患者来自MOMENTUM方案(NCT04075305),在1.5 T MRI直线加速器上接受SMART(50 Gy/5次),数据前瞻性收集。
主要发现
- 2019年2月至2025年9月共治疗118例LAPC患者;自首次SMART起中位OS为13.2个月(95%CI 10.4-15.9),2年OS率23.9%(95%CI 16.7-34.1)。
- 自诊断起中位OS为19.6个月(95%CI 17.8-24.0);自首次SMART起中位PFS为5.6个月(95%CI 4.3-7.1),2年PFS率14.8%(95%CI 8.8-24.9%)。
- 局部进展累积发生率1年为15.0%、2年为22.2%。
- 急性≥III级胃肠道毒性见于6/112例可评估患者(5.4%),包括1例IV级溃疡穿孔和1例V级十二指肠穿孔;晚期≥III级毒性见于3/93例可评估患者(3.2%)。
关键数值与推荐
- SMART剂量方案为50 Gy/5次,在1.5 T MRI直线加速器上实施。
- 疗效评价包括OS、PFS、局部进展风险和毒性,均基于前瞻性收集数据。
临床怎么用
- 对LAPC患者,SMART可作为局部控制手段,但需关注远处进展并重视胃肠道穿孔等严重毒性风险。
局限性
- 单中心前瞻性队列设计,样本量有限,结果需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This prospective single-center cohort study evaluated outcomes and toxicity after ablative stereotactic magnetic resonance imaging (MRI)-guided adaptive radiation therapy (SMART) in patients with locally advanced pancreatic cancer (LAPC). MATERIALS AND METHODS: Patients with LAPC treated within the MOMENTUM protocol (NCT04075305) received SMART (50 Gy/5 fractions) on a 1.5 T MRI-linear accelerator. Data were prospectively collected. Overall survival (OS), progression-free survival (PFS), risk of local progression, and toxicity were evaluated. RESULTS: Between February 2019 and September 2025, 118 patients with LAPC were treated. Median OS from the first SMART fraction was 13.2 months (95 % confidence interval [CI] 10.4-15.9), with a 2-year OS rate of 23.9 % (95 % CI 16.7-34.1). Median OS from diagnosis was 19.6 months (95 % CI 17.8-24.0). Median PFS from the first SMART fraction was 5.6 months (95 % CI 4.3-7.1), and 2-year PFS was 14.8 % (95 % CI 8.8-24.9 %). The cumulative incidence of local progression was 15.0 % at 1 year and 22.2 % at 2 years. Acute grade ≥ III gastrointestinal toxicity occurred in 6/112 assessed patients (5.4 %), including one grade IV ulcer perforation and one grade V duodenal perforation. Late grade ≥ III toxicity occurred in 3/93 assessed patients (3.2 %). CONCLUSION: SMART provided encouraging local control with limited severe toxicity in patients with LAPC, while distant progression remained the dominant pattern of failure.
引用
- Hartfelt PB, Bisgaard ALH, Ejlsmark MW, et al. Stereotactic MRI-guided adaptive radiation therapy (SMART) for locally advanced pancreatic cancer: A prospective single-center cohort study. Radiother Oncol. 2026. PMID: 42822782. doi:10.1016/j.radonc.2026.111790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。